United Therapeutics
Clinical trials sponsored by United Therapeutics, explained in plain language.
-
Major drug trial extends to track long-term effects in 1,000 PAH patients
Disease control ENROLLING_BY_INVITATIONThis study continues testing ralinepag, an experimental medication for pulmonary arterial hypertension (PAH), to understand its long-term safety and effectiveness. It enrolls 1,000 participants who have already taken ralinepag in previous studies and are already on standard PAH m…
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New strategy aims to reverse heart damage in lung disease
Disease control OngoingThis study is testing if starting a specific medication called treprostinil early and increasing the dose quickly can improve heart function and potentially reverse heart damage in people with pulmonary arterial hypertension (PAH). It will involve about 52 participants who are al…
Phase: PHASE4 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Six-year safety check for inhaled lung fibrosis drug begins
Disease control ENROLLING_BY_INVITATIONThis study follows people who were in previous trials of an inhaled medication called treprostinil for progressive lung scarring diseases. It aims to check the long-term safety and side effects of the drug over up to six years. Only people who completed specific earlier studies a…
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC